{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:30Z","timestamp":1793830470845,"version":"4.6.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with <jats:sup>18<\/jats:sup>F-FDG PET\/CT. However, its role in response evaluation remains unexplored. We propose a <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT\u2013based response evaluation criterion and evaluate its utility compared with International Myeloma Working Group (IMWG) criteria and <jats:sup>18<\/jats:sup>F-FDG PET\/CT\u2013based response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>In this prospective single-center study, 40 treatment-naive myeloma patients were recruited between February 2021 and April 2023. Both <jats:sup>68<\/jats:sup>Ga-Pentixafor and <jats:sup>18<\/jats:sup>F-FDG PET\/CT were performed at baseline and at follow-up (7.2\u00a0mo-median). Response to treatment was evaluated using the proposed <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT criteria and compared with responses assessed by IMWG and <jats:sup>18<\/jats:sup>F-FDG PET\/CT. Progression-free survival (PFS) and overall survival (OS) were analyzed and compared using Kaplan-Meier survival curves.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the 40 newly diagnosed MM patients [median age: 56.5 years (IQR 45.25 to 63.75); 24 men], <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT was positive in a greater proportion of patients than <jats:sup>18<\/jats:sup>F-FDG PET\/CT [90% (36\/40) vs. 67.5% (27\/40); <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02] thus, adequately evaluated response in additional 27.5% (11\/40) of cases. Using the proposed criteria for <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT, significant differences in PFS were observed across response categories [complete response (CR)\u2014not reached, partial response (PR)\u201426.2\u00a0mo, progressive disease (PD)\u201315.3\u00a0mo; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.001]. Among patients achieving \u2265very good partial response (VGPR) as per IMWG, those with positive <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT had shorter PFS compared with those with negative findings (median PFS: 34.2\u00a0mo vs. not reached; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.056), whereas no significant difference was noted with <jats:sup>18<\/jats:sup>F-FDG PET\/CT (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.68). In addition, on follow-up of patients with negative <jats:sup>18<\/jats:sup>F-FDG at the response, those with discordant <jats:sup>68<\/jats:sup>Ga-Pentixafor findings had significantly shorter PFS (17.73\u00a0mo vs. not reached; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.010) compared with those with concordant negative findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-Pentixafor PET\/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and <jats:sup>18<\/jats:sup>F-FDG PET\/CT\u2013based criteria.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005731","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:00:23Z","timestamp":1741327223000},"page":"e331-e339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["68Ga-Pentixafor PET\/CT\u2013Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18F-FDG\u2013Based Response"],"prefix":"10.1097","volume":"50","author":[{"given":"Harneet","family":"Kaur","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-3514","authenticated-orcid":false,"given":"Suraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Watts","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Clinical Hematology and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-8299","authenticated-orcid":false,"given":"Man Updesh Singh","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Hematology, Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4154","authenticated-orcid":false,"given":"Sreejesh","family":"Sreedharanunni","sequence":"additional","affiliation":[{"name":"Hematology, Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5707","authenticated-orcid":false,"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-8491","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Clinical Hematology and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"eClinicalMedicine"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG\u2013PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2967\/jnumed.118.217539","article-title":"Hexokinase-2 expression in 11C-methionine-positive, 18F-FDG-negative multiple myeloma","volume":"60","author":"Kircher","year":"2019","journal-title":"J Nucl Med"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J Nucl Med"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"20211272","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT: comparison with 18F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br J Radiol"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","article-title":"68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT","volume":"51","author":"Chen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma\u2014comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijnm.ijnm_216_20","article-title":"Automated radiosynthesis, quality control, and biodistribution of Ga-68 pentixafor: first Indian experience","volume":"36","author":"Watts","year":"2021","journal-title":"Indian J Nucl Med"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/diagnostics11020230","article-title":"Positron emission tomography (PET) imaging of multiple myeloma in a post-treatment setting","volume":"11","author":"Ferrarazzo","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"R26-20250613","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/RLU.0000000000003760","article-title":"Chemokine receptor 4\u2013targeted 68Ga-pentixafor PET\/CT in response assessment of Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to: 18: F-FDG PET\/CT","volume":"46","author":"Pan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor","volume":"56","author":"Herrmann","year":"2015","journal-title":"J Nucl Med"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:59Z","timestamp":1749816059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005731","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}